CARA - Cara Therapeutics, Inc.

4.85
0.098   2.029%

Share volume: 53,673
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$4.75
0.10
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 25%
Dept financing 18%
Liquidity 75%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.01%
1 Month
-3.23%
3 Months
0.03%
6 Months
1,755.37%
1 Year
475.60%
2 Year
3.07%
Key data
Stock price
$4.85
P/E Ratio 
0.00
DAY RANGE
$4.82 - $5.14
EPS 
-$2.84
52 WEEK RANGE
$0.23 - $6.36
52 WEEK CHANGE
$471.11
MARKET CAP 
27.976 M
YIELD 
N/A
SHARES OUTSTANDING 
54.847 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
-0.01
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$20,022
AVERAGE 30 VOLUME 
$12,818
Company detail
CEO: Christopher Posner
Region: US
Website: caratherapeutics.com
Employees: 80
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)

Recent news
loading